Document is current

Article History

Received: 21 November 2022

Accepted: 27 December 2022

First Online: 11 January 2023

Declarations

:

: There are no financial or other relations that could lead to a conflict of interest. The authors report following financial activities outside the submitted work: MO, TR, HK, OKS and JB have reported no financial relationships. PE has received consultation fee from Astra Zeneca, lecture fee from Abbvie and reimbursement of congress costs from Mylan and Abbvie. AK has received lecture fees from Abbvie. JH has received consultation fee from Abbvie, Amgen, Boehringer Ingelheim and Novartis, lecture fees from Boehringer Ingelheim and reimbursement of congress costs from Abbvie, Medac, Novartis and Pfizer. ES has received reimbursement of congress costs from Abbvie, Novartis, Pfizer, UCB, Janssen and MSD. LA has received reimbursement of congress costs from Orion. HN has received reimbursement of congress costs from Celltrion. AP has received consultation fee from MSD, lecture fees from MSD, Novartis, UCB, Pfizer, Eli Lilly, Amgen, Boehringer Ingelheim, Abbvie, Novo Nordisk, Celgene and reimbursement of congress costs from Janssen. KS has received consultation fee from Abbvie and reimbursement of congress costs from Abbvie, Novartis and Pfizer. SK has received reimbursement of congress costs from Abbvie, UCB and Medac.

: The studies were performed according to the principles of the Declaration of Helsinki and approved by the Ethics Committee of the Kuopio University Hospital (75/2001, 127/2009 and 1689/2019) and the Rheumatism Foundation Hospital (1991).

: All patients included in the studies 2010 and 2020–2021 gave a written consent.